AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner... Show more
ABCL's Aroon Indicator triggered a bullish signal on June 27, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 108 similar instances where the Aroon Indicator showed a similar pattern. In of the 108 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on May 30, 2025. You may want to consider a long position or call options on ABCL as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ABCL just turned positive on May 29, 2025. Looking at past instances where ABCL's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
ABCL moved above its 50-day moving average on June 03, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABCL crossed bullishly above the 50-day moving average on June 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in of 205 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where ABCL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ABCL broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.053) is normal, around the industry mean (16.345). P/E Ratio (0.000) is within average values for comparable stocks, (58.407). ABCL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.310). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (46.083) is also within normal values, averaging (252.768).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with CRSP. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then CRSP could also see price increases.
Ticker / NAME | Correlation To ABCL | 1D Price Change % | ||
---|---|---|---|---|
ABCL | 100% | -3.48% | ||
CRSP - ABCL | 61% Loosely correlated | +1.69% | ||
RXRX - ABCL | 59% Loosely correlated | -6.85% | ||
ABSI - ABCL | 57% Loosely correlated | -3.32% | ||
VCYT - ABCL | 56% Loosely correlated | +2.13% | ||
BEAM - ABCL | 55% Loosely correlated | -1.98% | ||
More |